Flush with $85 million in cash from its May 2013 IPO, armed with an outstanding scientific hypothesis, staffed by a world expert on leukemia, and nearly through with phase 2 clinical trials, Ambit Biosciences (AMBI) seems to be on the fast track to success. At the end of May, the esteemed private equity firm Orbimed purchased almost 1.5 million shares. The stock has nearly doubled to $13.52 since the beginning of July. Citigroup has given the company a rating of Outperform. Yet despite these excellent optics, careful review of the science and the economics indicates that common shareholders will almost certainly lose money, and probably all of it.
Ambit currently has four drugs...
Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: